Norinchukin Bank The Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Norinchukin Bank The increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,098 shares of the biopharmaceutical company’s stock after purchasing an additional 5,726 shares during the period. Norinchukin Bank The’s holdings in Gilead Sciences were worth $6,290,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Ossiam grew its stake in Gilead Sciences by 3.2% during the fourth quarter. Ossiam now owns 31,975 shares of the biopharmaceutical company’s stock valued at $2,954,000 after acquiring an additional 1,006 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of Gilead Sciences by 217.3% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 466,506 shares of the biopharmaceutical company’s stock worth $43,091,000 after buying an additional 319,498 shares in the last quarter. Capital International Inc. CA boosted its position in shares of Gilead Sciences by 23.8% during the 4th quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company’s stock valued at $28,839,000 after acquiring an additional 60,035 shares during the last quarter. Carbahal Olsen Financial Services Group LLC bought a new position in Gilead Sciences during the fourth quarter valued at $317,000. Finally, First Trust Advisors LP lifted its holdings in shares of Gilead Sciences by 1.7% in the 4th quarter. First Trust Advisors LP now owns 2,962,221 shares of the biopharmaceutical company’s stock valued at $273,620,000 after acquiring an additional 48,442 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the transaction, the chief financial officer now directly owns 171,223 shares in the company, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,540,875 over the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $104.49 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market cap of $130.10 billion, a PE ratio of 282.40, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a fifty day moving average price of $109.16 and a 200-day moving average price of $97.45.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.02%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

Several research analysts have commented on GILD shares. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Oppenheimer raised their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. BMO Capital Markets boosted their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.